Point-of-care - Biosensors for Drug Efficacy and Patient Response Evaluation
We developed a novel point of care PIEB (Point-of-care In situ Evaluation Biosensor) BioChip to provide prognosis prediction and allow timely medical intervention for cancer patients. With the PIEB BioChip, establishing patient-derived models will be easy, enabling rapid diagnosis and evaluation of cancer patients. The PIEB BioChip can also be used for drug screening and integrated with various downstream analysis. We will collaborate with hospitals, research institutions and pharmaceutical companies on research and to provide them with products and services to support diagnosis, evaluation and intervention for cancer patients.
Team members
Dr Deng Yanlin* (Dept. of Biomedical Engineering, CityU)
Dr Liao Junchen (Dept. of Biomedical Engineering, CityU)
* Person-in-charge
(Info based on the team's application form)
Dr Liao Junchen (Dept. of Biomedical Engineering, CityU)
* Person-in-charge
(Info based on the team's application form)
Achievement(s)
- CityU HK Tech 300 Seed Fund (2021)
- US Patent Pending: HFP09125 (2020), 2020
- Publication: Deng Y, Liu S Y, Chua S L, et al. The effects of biofilms on tumor progression in a 3D cancer-biofilm microfluidic model[J]. Biosensors and Bioelectronics, 2021, 180: 113113.
Email